PPA-Containing NDA Drugs, Weight-Control Aids Subject Of FDA Formal Notice
This article was originally published in The Tan Sheet
Executive Summary
An FDA notice giving new drug application and ANDA holders an opportunity to object to FDA's plans to withdraw approval for PPA-containing decongestants also applies to manufacturers of extended-release weight-control products containing the ingredient, according to the agency.
You may also be interested in...
Bayer Dealt Setback in Alka-Seltzer PPA Case
A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation
Bayer Dealt Setback in Alka-Seltzer PPA Case
A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation
Bayer Dealt Setback in Alka-Seltzer PPA Case
A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation